DANONE (BSN.DE) Stock Fundamental Analysis
FRA:BSN - Deutsche Boerse Ag - FR0000120644 - Common Stock - Currency: EUR
Overall BSN gets a fundamental rating of 5 out of 10. We evaluated BSN against 57 industry peers in the Food Products industry. While BSN belongs to the best of the industry regarding profitability, there are concerns on its financial health. BSN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year BSN was profitable.
BSN had a positive operating cash flow in the past year.
In the past 5 years BSN has always been profitable.
BSN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
BSN's Return On Assets of 4.46% is fine compared to the rest of the industry. BSN outperforms 63.79% of its industry peers.
With a decent Return On Equity value of 11.34%, BSN is doing good in the industry, outperforming 67.24% of the companies in the same industry.
BSN has a better Return On Invested Capital (6.58%) than 60.34% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BSN is in line with the industry average of 7.01%.
The 3 year average ROIC (6.38%) for BSN is below the current ROIC(6.58%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROIC | 6.58% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
1.3 Margins
BSN has a better Profit Margin (7.37%) than 67.24% of its industry peers.
BSN's Profit Margin has been stable in the last couple of years.
BSN has a better Operating Margin (13.00%) than 72.41% of its industry peers.
BSN's Operating Margin has declined in the last couple of years.
With an excellent Gross Margin value of 49.70%, BSN belongs to the best of the industry, outperforming 81.03% of the companies in the same industry.
In the last couple of years the Gross Margin of BSN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% |
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), BSN is creating some value.
The number of shares outstanding for BSN has been increased compared to 1 year ago.
The number of shares outstanding for BSN has been reduced compared to 5 years ago.
The debt/assets ratio for BSN has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 2.43 indicates that BSN is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.43, BSN perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
BSN has a debt to FCF ratio of 4.89. This is a neutral value as BSN would need 4.89 years to pay back of all of its debts.
The Debt to FCF ratio of BSN (4.89) is better than 70.69% of its industry peers.
A Debt/Equity ratio of 0.66 indicates that BSN is somewhat dependend on debt financing.
BSN has a Debt to Equity ratio (0.66) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Altman-Z | 2.43 |
ROIC/WACC1.05
WACC6.26%
2.3 Liquidity
A Current Ratio of 0.93 indicates that BSN may have some problems paying its short term obligations.
BSN has a Current ratio of 0.93. This is in the lower half of the industry: BSN underperforms 77.59% of its industry peers.
BSN has a Quick Ratio of 0.93. This is a bad value and indicates that BSN is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 0.77, BSN is doing worse than 60.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 129.22% over the past year.
Measured over the past 5 years, BSN shows a small growth in Earnings Per Share. The EPS has been growing by 1.20% on average per year.
Looking at the last year, BSN shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
The Revenue has been growing slightly by 1.60% on average over the past years.
EPS 1Y (TTM)129.22%
EPS 3Y2.12%
EPS 5Y1.2%
EPS Q2Q%472.23%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
3.2 Future
BSN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.57% yearly.
BSN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.75% yearly.
EPS Next Y7.5%
EPS Next 2Y7.65%
EPS Next 3Y7.5%
EPS Next 5Y6.57%
Revenue Next Year4.17%
Revenue Next 2Y3.95%
Revenue Next 3Y3.97%
Revenue Next 5Y3.75%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
BSN is valuated rather expensively with a Price/Earnings ratio of 22.94.
Based on the Price/Earnings ratio, BSN is valued a bit more expensive than 62.07% of the companies in the same industry.
BSN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 29.35.
BSN is valuated rather expensively with a Price/Forward Earnings ratio of 18.18.
Based on the Price/Forward Earnings ratio, BSN is valued a bit more expensive than the industry average as 60.34% of the companies are valued more cheaply.
BSN is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 22.10, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.94 | ||
| Fwd PE | 18.18 |
4.2 Price Multiples
BSN's Enterprise Value to EBITDA ratio is in line with the industry average.
BSN's Price/Free Cash Flow is on the same level as the industry average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 16.78 | ||
| EV/EBITDA | 10.65 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
The decent profitability rating of BSN may justify a higher PE ratio.
PEG (NY)3.06
PEG (5Y)19.11
EPS Next 2Y7.65%
EPS Next 3Y7.5%
5. Dividend
5.1 Amount
BSN has a Yearly Dividend Yield of 3.05%.
Compared to an average industry Dividend Yield of 3.35, BSN pays a bit more dividend than its industry peers.
BSN's Dividend Yield is a higher than the S&P500 average which is at 2.33.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
5.2 History
The dividend of BSN has a limited annual growth rate of 1.58%.
Dividend Growth(5Y)1.58%
Div Incr Years2
Div Non Decr Years3
5.3 Sustainability
BSN pays out 66.80% of its income as dividend. This is not a sustainable payout ratio.
BSN's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP66.8%
EPS Next 2Y7.65%
EPS Next 3Y7.5%
FRA:BSN (3/7/2025, 7:00:00 PM)
71.8
+1.42 (+2.02%)
Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupFood, Beverage & Tobacco
GICS IndustryFood Products
Earnings (Last)
Earnings (Next)
Inst Owners54.28%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap48.79B
Analysts72.12
Price Target72.57 (1.07%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
Yearly Dividend2.1
Dividend Growth(5Y)1.58%
DP66.8%
Div Incr Years2
Div Non Decr Years3
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.74%
PT rev (3m)5.78%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.2%
EPS NY rev (3m)1.43%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.54%
Revenue NY rev (3m)1.05%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 22.94 | ||
| Fwd PE | 18.18 | ||
| P/S | 1.78 | ||
| P/FCF | 16.78 | ||
| P/OCF | 12.74 | ||
| P/B | 2.74 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.65 |
EPS(TTM)3.13
EY4.36%
EPS(NY)3.95
Fwd EY5.5%
FCF(TTM)4.28
FCFY5.96%
OCF(TTM)5.64
OCFY7.85%
SpS40.29
BVpS26.18
TBVpS-9.15
PEG (NY)3.06
PEG (5Y)19.11
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.46% | ||
| ROE | 11.34% | ||
| ROCE | 11.27% | ||
| ROIC | 6.58% | ||
| ROICexc | 8.06% | ||
| ROICexgc | 68% | ||
| OM | 13% | ||
| PM (TTM) | 7.37% | ||
| GM | 49.7% | ||
| FCFM | 10.62% |
ROA(3y)2.83%
ROA(5y)3.44%
ROE(3y)7.34%
ROE(5y)9%
ROIC(3y)6.38%
ROIC(5y)6.21%
ROICexc(3y)7.67%
ROICexc(5y)7.39%
ROICexgc(3y)52.44%
ROICexgc(5y)45.6%
ROCE(3y)10.98%
ROCE(5y)10.58%
ROICexcg growth 3Y19.7%
ROICexcg growth 5Y13.36%
ROICexc growth 3Y4.65%
ROICexc growth 5Y1.26%
OM growth 3Y-1.81%
OM growth 5Y-3.08%
PM growth 3Y-1.94%
PM growth 5Y-0.54%
GM growth 3Y1.56%
GM growth 5Y0.26%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 4.89 | ||
| Debt/EBITDA | 2.49 | ||
| Cap/Depr | 79.02% | ||
| Cap/Sales | 3.37% | ||
| Interest Coverage | 20.69 | ||
| Cash Conversion | 81.04% | ||
| Profit Quality | 144.05% | ||
| Current Ratio | 0.93 | ||
| Quick Ratio | 0.77 | ||
| Altman-Z | 2.43 |
F-Score7
WACC6.26%
ROIC/WACC1.05
Cap/Depr(3y)59.49%
Cap/Depr(5y)65.43%
Cap/Sales(3y)3.2%
Cap/Sales(5y)3.59%
Profit Quality(3y)220.86%
Profit Quality(5y)178.79%
High Growth Momentum
Growth
EPS 1Y (TTM)129.22%
EPS 3Y2.12%
EPS 5Y1.2%
EPS Q2Q%472.23%
EPS Next Y7.5%
EPS Next 2Y7.65%
EPS Next 3Y7.5%
EPS Next 5Y6.57%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y4.08%
Revenue growth 5Y1.6%
Sales Q2Q%1.24%
Revenue Next Year4.17%
Revenue Next 2Y3.95%
Revenue Next 3Y3.97%
Revenue Next 5Y3.75%
EBIT growth 1Y2.24%
EBIT growth 3Y2.2%
EBIT growth 5Y-1.53%
EBIT Next Year37.33%
EBIT Next 3Y14.67%
EBIT Next 5Y9.76%
FCF growth 1Y11.98%
FCF growth 3Y6.14%
FCF growth 5Y3.12%
OCF growth 1Y11.24%
OCF growth 3Y3.31%
OCF growth 5Y2.15%